Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway.
Aberrant activation of Wnt/β-catenin signaling promotes development and progression of various malignant neoplasms. Recent studies observed that the Wnt pathway is constitutively active in myeloma cells and promotes an exaggerated proliferation. Thus, the Wnt signaling pathway might be an attractive therapeutic target for multiple myeloma. In this study, we identified piceatannol as an inhibitor of the Wnt/β-catenin pathway and as a potent inducer of apoptosis in myeloma cells. Interestingly, healthy cells remained mainly unaffected. These results reveal a significant selective induction of apoptosis by piceatannol and suggest a significant in vivo effect against multiple myeloma.
['Schmeel|Frederic Carsten|FC|', 'Schmeel|Leonard Christopher|LC|', 'Kim|Young|Y|', 'Schmidt-Wolf|Ingo G H|IG|']
D000818:Animals D017209:Apoptosis D002460:Cell Line D045744:Cell Line, Tumor D049109:Cell Proliferation D002470:Cell Survival D005347:Fibroblasts D006801:Humans D007167:Immunotherapy D020128:Inhibitory Concentration 50 D051379:Mice D009101:Multiple Myeloma D011419:Propidium D013267:Stilbenes D016896:Treatment Outcome D051153:Wnt Proteins D060449:Wnt Signaling Pathway D051176:beta Catenin
myeloma beta-catenin signaling Wnt pathway Wnt inhibitor immuno therapy